About: Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
Creator	Akahori, Y Aoyagi, T Ishii, K Kaku, M Kanno, E Kawakami, K Kudo, D Kushimoto, S Maruyama, R Yamamoto, H Toyama, †
Source	Medline; PMC
abstract	Acute respiratory distress syndrome (ARDS) is accompanied by severe lung inflammation induced by various diseases. Despite the severity of the symptoms, therapeutic strategies have been ineffective. High mobility group box 1 (HMGB1), which was identified originally as a DNA binding protein, has been proposed as a mediator of acute lung injury. In addition to its anti-coagulant activity, recombinant thrombomodulin (rTM) possesses an ability to suppress the inflammatory response through neutralizing HMGB1. T regulatory (T(reg)) cells in the lungs are reported to modify innate immune responses during resolution of acute lung injury. In the present study, we investigated the therapeutic effect of rTM, and the contribution of T(reg) cells to this effect, in a mouse model of severe ARDS. C57BL/6 mice received sequential intratracheal administration of α-galactosylceramide (α-GalCer) and lipopolysaccharide (LPS), which resulted in the development of severe ARDS. HMGB1 levels in the lungs increased to a higher level in ARDS mice compared to those in mice treated with LPS alone. HMGB1 was expressed in the infiltrating neutrophils and macrophages in lungs. T(reg) cells were reduced significantly in the lungs of ARDS mice compared to those in mice treated with LPS alone. rTM administration prolonged the survival time and ameliorated the development of ARDS, which was associated with increased T(reg) cells and synthesis of interleukin (IL)-10 and transforming growth factor (TGF)-β in the lungs. These results suggest that HMGB1 is involved in the development of severe ARDS and rTM shows therapeutic effects through promoting the accumulation of T(reg) cells at the inflammatory sites.
has issue date	2013-07-04(xsd:dateTime)
bibo:doi	10.1111/cei.12106
bibo:pmid	23607598
has license	green-oa
sha1sum (hex)	bf907ceaf2eaa2cc38c0dbe93135042937b36d14
schema:url	https://doi.org/10.1111/cei.12106
resource representing a document's title	Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
has PubMed Central identifier	PMC3722928
has PubMed identifier	23607598
schema:publication	Clinical & Experimental Immunology
resource representing a document's body	covid:bf907ceaf2eaa2cc38c0dbe93135042937b36d14#body_text
is schema:about of	named entity 'mice' named entity 'mouse' named entity 'mice' named entity 'induced' named entity 'high mobility group' named entity 'acute lung injury' named entity 'ARDS' named entity 'study' named entity 'DNA' named entity 'innate immune responses' named entity 'therapeutic' named entity 'administration' named entity 'sites' named entity 'Treg cells' named entity 'effects' named entity 'Treg cells' named entity 'severe' named entity 'investigated' named entity 'treated' named entity 'administration' named entity 'strategies' named entity 'inflammatory' named entity 'ARDS' named entity 'acute lung injury' named entity 'lungs' named entity 'therapeutic strategies' named entity 'inflammatory response' named entity 'anticoagulant' named entity 'innate immune responses' named entity 'HMGB1' named entity 'ARDS' named entity 'lungs' named entity 'HMGB1' named entity 'therapeutic effects' named entity 'mice' named entity 'inflammatory' named entity 'accumulation' named entity 'mice' named entity 'mice' named entity 'IL-1b' named entity 'ALI' named entity 'conjugated' named entity 'hybridoma cells' named entity 'TGF-b' named entity 'LPS' named entity 'trachea' named entity 'HMGB1' named entity 'IFN-g' named entity 'mice' named entity 'CD4 +' named entity 'haemorrhage' named entity 'chicken' named entity 'leucocytes' named entity 'lung injury' named entity 'trachea' named entity 'time-point' named entity 'TGF-b' named entity 'HMGB1' named entity 'Tohoku University' named entity 'lymphocytes' named entity 'pathological condition' named entity 'DMSO' named entity 'HMGB1' named entity 'ARDS' named entity 'lipopolysaccharide' named entity 'HMGB1' named entity 'IFN-g' named entity 'C57BL/6' named entity 'PBS' named entity 'HMGB1' named entity 'mice'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software